News for Amicus Therapeutics, Inc. (FOLD)

Amicus Therapeutics is growing steadily with Galafold and a promising Pompe therapy, targeting $1B revenue by 2028. See why FOLD stock is a buy.

Summary Amicus Therapeutics Inc (FOLD) announced on June 3, 2025, the publication of a post-hoc analysis from the PROPEL study in the journal "Muscle and Nerve.

Amicus Therapeutics (FOLD) has unveiled a publication detailing a post-hoc analysis from the PROPEL study, focusing on adults with late-onset Pompe disease. Thi

PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics ( FOLD), today announced the publication of a post-hoc analysis of data from the ERT-e

Summary Amicus Therapeutics Inc (FOLD), a global biotechnology company dedicated to developing innovative medicines for rare diseases, announced on May 30, 2025

**media[641248]**

On May 16, 2025, Redmile Group, LLC (Trades, Portfolio) executed a notable transaction involving Atara Biotherapeutics Inc. The firm added 263,506 shares of Ata

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Amicus Therapeutics, Inc.

**media[617245]**

In a recent update, UBS analyst Karl Chalabala has maintained a \

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsAndrew Faughnan - Vice President of...

Revenue: $125.2 million for Q1 2025, falling short of the estimated $135.86 million, yet marking a 15% increase year-over-year at constant exchange rates.Earni

In the high-stakes world of Wall Street, where Bitcoin and tech giants dominate the headlines, a quieter game is unfolding. Insiders—executives, directors, and institutional investors—are placing their bets on a different set of players: seven overlooked stocks with strong fundamentals and untapped potential. These aren’t the flashy names you’ll find trending on social media. They’re […]

The ASX200 closed up 0.24% at 8,145 points. The IT sector surged…

The ASX has been up 0.2% at around 8,140 points in morning…

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over […]

Summary Amicus Therapeutics Inc (FOLD), a global biotechnology company dedicated to developing innovative medicines for rare diseases, has announced it will hos

**media[600295]**

We recently published a list of 10 Best Low Priced Growth Stocks To Invest In. In this article, we are going to take a look at where Amicus Therapeutics, Inc.